Study Stopped
Study redesigned into three separate trials.
TMJ-1001 Bruxism Run-In/Pivotal Trial
A Pivotal Study of the TMJ NextGeneration(TradeMark) Compared to Occlusal Splint Treatment for Reduction in Nocturnal Bruxism Episodes and Monthly Migraine Episodes in Subjects Diagnosed With Sleep Bruxism
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The study is an open-label, prospective, multi-center, randomized, two treatment parallel, comparison study of the TMJ NextGeneration(TM) and custom-fit occlusal splint in the reduction of nocturnal bruxism episodes and monthly migraine episodes in subjects diagnosed with sleep bruxism and headaches.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Apr 2015
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2014
CompletedFirst Posted
Study publicly available on registry
October 21, 2014
CompletedStudy Start
First participant enrolled
April 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedMay 14, 2015
May 1, 2015
8 months
October 7, 2014
May 12, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change from Baseline (CFB) in bruxism episodes per hour of sleep
Baseline and Week 8
CFB in the number of migraine episodes per month
Baseline and Week 8
Secondary Outcomes (5)
CFB in the number of headache episodes per month
Baseline and Week 8
CFB in the in-clinic pain Visual Analogue Scale (VAS) scores
Baseline and Week 8
CFB in the average daily at-home pain VAS scores
Baseline and Week 8
CFB in the morning daily at-home pain VAS scores
Baseline and Week 8
CFB in the evening daily at-home pain VAS scores
Baseline and Week 8
Other Outcomes (1)
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Baseline and Week 8
Study Arms (2)
TMJ NextGeneration(TM)
ACTIVE COMPARATORThe TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
Standard Hard TMJD Splint
ACTIVE COMPARATORThe occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
Interventions
The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
Eligibility Criteria
You may qualify if:
- Subject is at least 18 years of age;
- Subject has had a diagnosis of sleep bruxism within the past 30 days;
- Subject is able to read and understand the ICF and has voluntarily provided written informed consent;
- Subject must have a minimum of 26 remaining teeth;
- Subject has recorded more than 50% of screening period diary pain VAS scores ≥40;
- Subject has been medically screened and diagnosed by a physician as having migraines;
- Subject has been prescribed and is using a triptan as a rescue medication for their migraine episodes;
- Subject has recorded ≥ 2 self-diagnosed migraine episodes in the screening diary;
- Subject has an average of ≥ 4 bruxism episodes per hour of sleep based on the screening sleep EMG evaluations;
- Subject is willing to comply with the usage instructions for the Bruxoff (sleep EMG evaluation) device.
- Subject is able to open their mouth at least 17 mm to be fitted for the TMJ NextGenerationTM device.
- Male Subjects are willing to have a clean shaven face on the nights that the Bruxoff device will be used;
- Subject agrees that when using the Bruxoff device to keep their cellular phone in another room.
You may not qualify if:
- Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;
- Subject has any sleep disorder other than bruxism;
- Subjects who have had direct trauma to the jaw;
- Subject experiences chronic migraines, \> 15 per month;
- Subject experiences secondary headaches (i.e. Arnold-Chiari syndrome and/or low pressure headaches) in the opinion of the Investigator;
- Subjects who have used an occlusal appliance to treat TMD within the previous six months;
- Subjects who have had prior TMJ or ear surgery;
- Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified;
- Subjects with visible or congenital ear deformity as observed on targeted physical exam that does not allow for fitting of the study device;
- Subjects who have taken a narcotic pain medication in the last seven days prior to Day -7 of the study;
- Subjects who have a history of ear pain unrelated to TMJ;
- Subjects who have a history of ear drainage in the past six months;
- Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam;
- Subjects whom the investigator believes may not be an appropriate candidate for an intra-oral splint due to missing or poor quality dentition or untreated pain of dental origin (pulpal pain, pericoronitis of wisdom teeth, or similar conditions);
- Subjects who, in the opinion of the investigator, cannot be properly fit with their assigned device;
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- TMJ Healthlead
- Cardiox Corporationcollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
simon blackburn, CCRA
Senior Director, Clinical Affairs
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 7, 2014
First Posted
October 21, 2014
Study Start
April 1, 2015
Primary Completion
December 1, 2015
Study Completion
December 1, 2015
Last Updated
May 14, 2015
Record last verified: 2015-05